Stockscreener 앱 받기
1.31
9.66%
-0.14
전일 마감가:
$1.45
열려 있는:
$1.45
하루 거래량:
1.06M
Relative Volume:
1.15
시가총액:
$184.87M
수익:
$15.53M
순이익/손실:
$-52.71M
주가수익비율:
-2.607
EPS:
-0.5025
순현금흐름:
$-59.00M
1주 성능:
-19.63%
1개월 성능:
-29.57%
6개월 성능:
-32.82%
1년 성능:
-53.21%
1일 변동 폭
$1.30
$1.49
1주일 범위
$1.30
$1.70
52주 변동 폭
$1.30
$3.10
Proqr Therapeutics N V Stock (PRQR) Company Profile
Compare PRQR vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PRQR
Proqr Therapeutics N V
|
1.31 | 184.87M | 15.53M | -52.71M | -59.00M | -0.5025 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-08-20 | 개시 | BofA Securities | Buy |
| 2026-03-12 | 재개 | Oppenheimer | Outperform |
| 2025-04-29 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-04-29 | 개시 | Evercore ISI | Outperform |
| 2025-03-10 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-01-10 | 개시 | Oppenheimer | Outperform |
| 2024-10-29 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-11-08 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2023-03-30 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-12-22 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2022-02-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-02-11 | 다운그레이드 | Raymond James | Strong Buy → Mkt Perform |
| 2022-02-11 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-02-01 | 개시 | Raymond James | Strong Buy |
| 2021-05-03 | 개시 | Stifel | Buy |
| 2021-03-25 | 재확인 | Citigroup | Buy |
| 2020-11-03 | 재개 | Cantor Fitzgerald | Overweight |
| 2019-03-12 | 재확인 | Chardan Capital Markets | Buy |
| 2018-12-19 | 개시 | RBC Capital Mkts | Outperform |
| 2018-11-15 | 개시 | Citigroup | Buy |
| 2018-09-19 | 개시 | Evercore ISI | Outperform |
| 2017-09-26 | 재확인 | JMP Securities | Mkt Outperform |
| 2016-06-20 | 개시 | Chardan Capital Markets | Neutral |
| 2014-10-15 | 개시 | Deutsche Bank | Buy |
| 2014-10-13 | 개시 | H.C. Wainwright | Buy |
모두보기
Proqr Therapeutics N V 주식(PRQR)의 최신 뉴스
ProQR Therapeutics' (PRQR) Buy Rating Reaffirmed at Chardan Capital - MarketBeat
FY2028 Earnings Estimate for PRQR Issued By HC Wainwright - MarketBeat
Press Releases about ProQR Therapeutics N.V.Ordinary Shares (Nasdaq:PRQR) - FinancialContent
ProQR Therapeutics N.V.Ordinary Shares (PRQR) Stock Price, News, Quote & History - financialcontent.com
HC Wainwright Has Lowered Expectations for ProQR Therapeutics (NASDAQ:PRQR) Stock Price - MarketBeat
Price to sales forward of ProQR Therapeutics N.V. – SWB:0PQ - TradingView
Obesity Market to Witness Strong Growth and Significant Market Expansion by 2036 – DelveInsight | Rhythm Pharma, Boehringer Ingelheim, D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical - Barchart.com
ProQR Therapeutics Initiates AX-0811 Clinical Trial Following First Participant Dosing - Kalkine Media
ProQR Therapeutics N.V.ADR Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
ProQR at Cantor conference: RNA editing pipeline gains speed By Investing.com - Investing.com Australia
ProQR at Cantor conference: RNA editing pipeline gains speed By Investing.com - Investing.com Nigeria
ProQR at Cantor conference: RNA editing pipeline gains speed By Investing.com - Investing.com South Africa
ProQR at Cantor conference: RNA editing pipeline gains speed By Investing.com - Investing.com India
ProQR at Cantor conference: RNA editing pipeline gains speed By Investing.com - Investing.com UK
ProQR doses first participant in AX-0811 phase 1 trial By Investing.com - Investing.com South Africa
ProQR Therapeutics Doses First Participant in Phase 1 Trial of Liver Disease Treatment - marketscreener.com
ProQR doses first participant in AX-0811 phase 1 trial - investing.com
ProQR doses first participant in AX-0811 phase 1 trial By Investing.com - Investing.com Canada
ProQR Doses First Participant in Phase 1 Trial of AX-0811 for Cholestatic Liver Diseases - TipRanks
ProQR doses first participant in AX-0811 phase 1 trial By Investing.com - Investing.com India
A liver disease trial has dosed its first volunteer. ProQR expects early study data in January 2027. - Stock Titan
ProQR Therapeutics (NASDAQ:PRQR) Shares Cross Above 50 Day Moving AverageShould You Sell? - marketbeat.com
Enterprise value to EBIT forward of ProQR Therapeutics N.V. – NASDAQ:PRQR - TradingView
ProQR Therapeutics N.V.ADR Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
CureVac NV (CVAC) Peer Comparison – Compare with Others - Value Research
ProQR to Participate in Upcoming Investor Conferences in September 2026 - markets.businessinsider.com
ProQR to Participate in Upcoming Investor Conferences in September 2026 - The Manila Times
ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Rating of "Moderate Buy" by Brokerages - marketbeat.com
ProQR Therapeutics N.V.ADR Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
ProQR Therapeutics (NASDAQ:PRQR) Share Price Crosses Above 50-Day Moving AverageWhat's Next? - marketbeat.com
ProQR Therapeutics NV (PRQR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Certain Warrants of ProQR Therapeutics N.V. are subject to a Lock-Up Agreement Ending on 24-AUG-2026. - marketscreener.com
Certain Common Stock of ProQR Therapeutics N.V. are subject to a Lock-Up Agreement Ending on 24-AUG-2026. - marketscreener.com
ProQR Therapeutics: Buy For Axiomer RNA Tech Validation And Other Catalysts (NASDAQ:PRQR) - Seeking Alpha
ProQR Therapeutics starts with Buy rating on st... - Pluang
Price to sales forward of ProQR Therapeutics N.V. – FWB:0PQ - TradingView
PRQR Looks 1.8% Undervalued on GF Value™ at $2.45 - GuruFocus
PRQR Initiates Coverage by B of A Securities -- Price Target Ann - GuruFocus
ProQR a new buy at BoA on RNA-editing platform - Seeking Alpha
BofA Securities initiates ProQR stock with buy on liver therapy By Investing.com - Investing.com Canada
ProQR Therapeutics (NASDAQ:PRQR) Earns Buy Rating from Analysts at Bank of America - MarketBeat
BofA Securities initiates ProQR stock with buy on liver therapy By Investing.com - Investing.com India
BofA Securities initiates ProQR stock with buy on liver therapy By Investing.com - Investing.com UK
BofA Securities initiates ProQR stock with buy on liver therapy - Investing.com
BofA Securities initiates ProQR stock with buy on liver therapy - Investing.com
ProQR (PRQR) Levels: Climbs 3.26% to $2.22 in the Latest Session; Key Range - vinanet.vn
ProQR (PRQR) Levels: Climbs 3.26% to $2.22 in the Latest Session; Key Range - siam.in
HC Wainwright Expects Lower Earnings for ProQR Therapeutics - MarketBeat
ProQR Therapeutics Virtual Investor Event Transcript - GuruFocus
Equities Analysts Set Expectations for PRQR FY2030 Earnings - MarketBeat
Proqr Therapeutics N V (PRQR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Proqr Therapeutics N V 주식 (PRQR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Filius Bart | Director |
Jul 17 '26 |
Buy |
1.72 |
150,000 |
257,925 |
300,000 |
| de Boer Daniel Anton | Chief Executive Officer |
Jul 09 '26 |
Buy |
1.74 |
150,000 |
261,000 |
300,000 |
| de Boer Daniel Anton | Chief Executive Officer |
Jul 07 '26 |
Buy |
1.59 |
150,000 |
238,500 |
150,000 |
| Filius Bart | Director |
Jun 26 '26 |
Buy |
1.54 |
150,000 |
231,000 |
150,000 |
4.22%
자본화:
|
볼륨(24시간):